程序性死亡受体1及其配体在眼睑基底细胞癌中的表达及临床意义  

Expression and clinical significance of PD-1 and PD-L1 in basal cell carcinoma of eyelids

作　　者：宁婵慧 任晓霞[1] 魏彤心[1] 张魏魏[1] 柴雪荣 Ning Chanhui;Ren Xiaoxia;Wei Tongxin;Zhang Weiwei;Chai Xuerong(Department of Plastics,Shanxi Eye Hospital,Taiyuan,Shanxi 030002,China)

机构地区：[1]山西省眼科医院眼整形科,山西太原030002

出　　处：《中国药物与临床》2023年第8期505-508,I0001,共5页Chinese Remedies & Clinics

基　　金：山西省眼科医院院内科研基金(C201809)。

摘　　要：目的 探讨程序性死亡受体1 (programmed cell death-1,PD-1)与程序性死亡配体1(programmed cell death ligand 1,PD-L1)在眼睑基底细胞癌(BCC)中的表达及其临床意义。方法 收集2018—2021年于山西省眼科医院眼整形科行手术切除的眼睑基底细胞癌患者标本共20例作为病例组,取癌周围组织5例为对照组,采用免疫组织化学方法检测2组中PD-1、PD-L1的表达情况,利用图像分析系统测定2组中PD-1、PD-L1表达的平均阳性面积率及平均光密度。结果 在眼睑基底细胞癌组织中,PD-1、PDL1呈高表达,在癌周组织中,PD-1、PD-L1呈低表达;图像分析结果显示,PD-1、PD-L1在病例组的表达均高于对照组,2组差异有统计学意义(P<0.05)。结论 PD-1/PD-L1通路在基底细胞癌的发病中起关键作用,为PD-1/PD-L1通路抑制剂在基底细胞癌患者中的作用的临床试验提供了理论基础。Objective To investigate the expression of programmed cell death receptor 1(PD-1)and pro-grammed cell death ligand 1(PD-L1)in basal cell carcinoma(BCC)of eyelids and their clinical significance.Methods A total of 20 specimens(study group)were collected from eyelid BCC patients who underwent surgical resection in department of oculoplasty of shanxi provincial eye hospital between January 2018 and December 2021.Five specimens of cancer-adjacent tissues were included as the control group.The two groups were mea-sured for the expression of PD-1 and PD-L1 by immunohistochemistry.An image analysis system was used to mea-sure the mean percentages of positive area and mean optical densities of PD-1 and PD-L1 expression in the two groups.Results The expression of PD-1 and PD-L1 was high in eyelid BCC tissues and was low in cancer-adja-cent tissues.The image analysis showed that PD-1 and PD-L1 expression was higher in the study group than that in the control group,with significant differences(P<0.05).Conclusion The PD-1/PD-L1 pathway plays a critical role in the pathogenesis of BCC.This theoretically underpins future clinical trials on the effects of PD-1/PD-L1 in-hibitors in BCC patients.

关 键 词：癌 基底细胞 程序性细胞死亡受体1 免疫检查点抑制剂 免疫组织化学 

分 类 号：R739.71[医药卫生—肿瘤]